ZINFORO

Reason for request

Clinical Benefit

Insufficient	insufficient for the treatment of community-acquired pneumonias (CAP).
Substantial	substantial for the treatment of complicated skin and soft tissue infections (cSSTI)

Clinical Added Value

minor

In view of : - its activity against methicillin-resistant Staphylococcus and clinical efficacy which is not inferior to that of the combination vancomycin/aztreonam in patients suffering from mild to moderate skin or soft tissue infections, - a satisfactory safety profile similar to that of the injectable cephalosporins which are currently marketed, - simplification of treatment (reduced number of injections and less monitoring than vancomycin), the Committee considers that ZINFORO provides a minor improvement in actual benefit (IAB IV) for the management of “complicated skin and soft tissue infections ”.